Dual inhibition of both endocannabinoid-degrading enzymes (FAAH and MAGL) reduced migraine-like pain and neuroinflammatory markers in rats, likely through CB1 receptor activation.
Migraine researchers, pain pharmacologists, endocannabinoid system investigators
Dual FAAH/MAGL inhibition reduced both pain and CGRP in central and peripheral sites
What the researchers found
The dual FAAH/MAGL inhibitor JZL195 significantly reduced nitroglycerin-induced trigeminal hyperalgesia and pain-associated behavior, likely via CB1 receptors. It decreased CGRP and cytokine gene expression in both central (cervical spinal cord) and peripheral (trigeminal ganglion) structures, plus reduced CGRP serum levels. However, it did not improve nitroglycerin-induced hypomotility or anxiety.
Why it matters
Individual FAAH or MAGL inhibitors have shown promise for migraine. Dual inhibition may provide synergistic pain relief by boosting both anandamide and 2-AG simultaneously, with broader anti-inflammatory effects across central and peripheral pain pathways.
The numbers in context
JZL195 reduced trigeminal hyperalgesia and pain behavior via CB1; decreased CGRP gene expression in cervical spinal cord and trigeminal ganglion; reduced CGRP serum levels; decreased cytokine gene expression centrally and peripherally; no effect on hypomotility or anxiety
How the study worked
Rats received nitroglycerin to induce migraine-like features, then JZL195 (dual FAAH/MAGL inhibitor). Assessed orofacial formalin test (trigeminal pain), open field (activity/anxiety), CGRP serum levels, and gene expression of CGRP and cytokines in spinal cord and trigeminal ganglion.
What this study cannot tell us
Acute animal model of migraine, not chronic. Dual inhibition may have more side effects than selective inhibition. CB1-mediated effects could include psychoactive properties. Does not address tolerability or abuse potential.
How to read the evidence
Well-designed preclinical study with multiple endpoints, but limited by acute model and male rats only.
When this study was published
Published in 2021.
The bigger picture
The simultaneous reduction of CGRP (the target of current migraine antibody drugs) and inflammatory cytokines across multiple pain processing sites suggests endocannabinoid boosting could offer a multi-target approach to migraine treatment.
Questions still open
- Would dual endocannabinoid enhancement be tolerable in humans given CB1-mediated effects? How does this approach compare to existing CGRP-targeting migraine treatments?
Common questions
How could endocannabinoids help migraines?
Is this the same as using cannabis for migraines?
Read the original research
Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine.
Cells, 10(10)
Citation
Greco, Rosaria; Demartini, Chiara; Francavilla, Miriam; Zanaboni, Anna Maria; Tassorelli, Cristina. (2021). Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine.. Cells, 10(10). https://doi.org/10.3390/cells10102543
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk